Overall, our study reveal that combined treatment with AdV-D24-ICOSL-CD40L and anti-PD1 showed higher anti-tumour activity and a synergistic anti-cancer effect against both melanoma and mesothelioma animal models. This evidence concerns the gene PDCD1 and mesothelioma.